Exelixis, Inc. - Common Stock (NQ:EXEL)

59.44 +1.05 (+1.80%)

Delayed Quote Updated: 3:40 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

23 24 Next >

Navigating 16 Analyst Ratings For Exelixis ↗

October 21, 2024

Via Benzinga

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

October 18, 2024

In a market where value is scarce, EXELIXIS INC (NASDAQ:EXEL) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

October 15, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

October 15, 2024

From Exelixis, Inc.

Via Business Wire

Key Takeaways From Exelixis Analyst Ratings ↗

October 04, 2024

Via Benzinga

A Closer Look at 5 Analyst Recommendations For Exelixis ↗

September 18, 2024

Via Benzinga

NASDAQ:EXEL, an undervalued stock with good fundamentals. ↗

August 15, 2024

Don't overlook EXELIXIS INC (NASDAQ:EXEL)—it's a hidden gem with strong fundamentals and an attractive price tag.

Via Chartmill

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

October 14, 2024

From Exelixis, Inc.

Via Business Wire

Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas ↗

October 13, 2024

It is Fall clean up time. Sell lagging and sagging companies.

Via Talk Markets

NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals. ↗

September 27, 2024

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

Via Chartmill

2 Growth Stocks to Buy With Less Than $100 ↗

September 26, 2024

No need to break the bank to get in on these likely long-term winners.

Via The Motley Fool

Expert Outlook: Exelixis Through The Eyes Of 5 Analysts ↗

August 08, 2024

Via Benzinga

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

September 16, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

September 15, 2024

From Exelixis, Inc.

Via Business Wire

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

September 06, 2024

EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.

Via Chartmill

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

August 28, 2024

From Exelixis, Inc.

Via Business Wire

3 Stocks to Buy for a Soft Landing, If There Is One

August 15, 2024

Recent economic data is reigniting talk about a soft landing for the economy; here are three stocks to consider if a soft landing materializes

Via MarketBeat

Topics Economy

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review ↗

August 09, 2024

After Monday's panicked global sell-off, markets have calmed down.

Via Investor's Business Daily

Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results ↗

August 07, 2024

Exelixis reports strong Q2 earnings with adjusted EPS of $0.84, surpassing estimates. The CONTACT-02 trial for mCRPC showed significant PFS benefit but OS did not achieve statistical significance....

Via Benzinga

US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity' ↗

August 07, 2024

Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by...

Via Benzinga

Topics Stocks

Exelixis (EXEL) Q2 2024 Earnings Call Transcript ↗

August 07, 2024

EXEL earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

EXEL Stock Earnings: Exelixis Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

EXEL stock results show that Exelixis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update

August 06, 2024

From Exelixis, Inc.

Via Business Wire

Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday? ↗

August 06, 2024

U.S. stock markets saw a strong recovery on Tuesday, with both the S&P 500 and the Nasdaq 100 climbing over 2%, nearly offsetting Monday’s losses. Investors took advantage of recent volatility to buy...

Via Benzinga

Topics Economy Stocks

Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors

August 06, 2024

From Exelixis, Inc.

Via Business Wire

US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction ↗

August 06, 2024

Strong sell-off may be viewed as an opportunity to load up beaten-down stocks but traders may seek evidence regarding sustainability of uptrend.

Via Benzinga

Topics Stocks

Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

July 23, 2024

From Exelixis, Inc.

Via Business Wire

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

July 18, 2024

EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.

Via Chartmill

7 Cheap Biotech Stocks With Major Upside Potential ↗

July 09, 2024

While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.

Via InvestorPlace

When you look at NASDAQ:EXEL, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

June 27, 2024

When you look at EXELIXIS INC (NASDAQ:EXEL), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.